Home » Stocks » NBY

NovaBay Pharmaceuticals, Inc. (NBY)

Stock Price: $0.731 USD -0.019 (-2.51%)
Updated Jun 11, 2021 4:00 PM EDT - Market closed
Market Cap 30.67M
Revenue (ttm) 9.85M
Net Income (ttm) -10.98M
Shares Out 41.78M
EPS (ttm) -0.29
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day June 11
Last Price $0.731
Previous Close $0.750
Change ($) -0.019
Change (%) -2.51%
Day's Open 0.746
Day's Range 0.720 - 0.769
Day's Volume 534,075
52-Week Range 0.515 - 1.940

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

EMERYVILLE, Calif.--(BUSINESS WIRE)--NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a pharmaceutical company focusing on expanding its presence in the eye and skin care market, announces the avail...

3 weeks ago - Business Wire

EMERYVILLE, Calif.--(BUSINESS WIRE)--NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) reports financial results for the three months ended March 31, 2021 and provides a business update. “Our focus on...

1 month ago - Business Wire

EMERYVILLE, Calif.--(BUSINESS WIRE)--NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) announces it will report financial results for the three months ended March 31, 2021 after market close on Thursd...

1 month ago - Business Wire

EMERYVILLE, Calif.--(BUSINESS WIRE)--NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) reports financial results for the three and twelve months ended December 31, 2020 and provides a business update....

2 months ago - Business Wire

EMERYVILLE, Calif.--(BUSINESS WIRE)--NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) announces it will report financial results for the three and 12 months ended December 31, 2020 after market close...

2 months ago - Business Wire

EMERYVILLE, Calif.--(BUSINESS WIRE)--NovaBay Pharmaceuticals (NYSE American: NBY), a pharmaceutical company focusing on commercializing Avenova® for the eye care market and CelleRx® Clinical Reset™ for ...

3 months ago - Business Wire

EMERYVILLE, Calif.--(BUSINESS WIRE)---- $NBY #Avenova--NovaBay announces Avenova and CelleRx Clinical Reset to be available in brick-and-mortar stores.

4 months ago - Business Wire

EMERYVILLE, Calif.--(BUSINESS WIRE)-- #Avenova--NovaBay Pharmaceuticals announces its proprietary hypochlorous acid solution has received EPA approval for SARS-CoV-2 kill claim.

5 months ago - Business Wire

EMERYVILLE, Calif.--(BUSINESS WIRE)--NovaBay Pharmaceuticals Expands Avenova's Geographic Reach to Australia with New Exclusive Distribution Agreement

6 months ago - Business Wire

NovaBay Pharmaceuticals, Inc. (NBY) CEO Justin Hall on Q3 2020 Results - Earnings Call Transcript

6 months ago - Seeking Alpha

EMERYVILLE, Calif.--(BUSINESS WIRE)--NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) reports financial results for the three and nine months ended September 30, 2020 and provides a business update. ...

7 months ago - Business Wire

EMERYVILLE, Calif.--(BUSINESS WIRE)-- #CelleRx--NovaBay Launches CelleRx Clinical Reset and enters the beauty market

7 months ago - Business Wire

EMERYVILLE, Calif.--(BUSINESS WIRE)---- $NBY #Avenova--NovaBay Pharmaceuticals to announce third quarter 2020 financial results on November 12

7 months ago - Business Wire

EMERYVILLE, Calif.--(BUSINESS WIRE)-- #Avenova--NovaBay regains compliance with NYSE American listing standards

8 months ago - Business Wire

EMERYVILLE, Calif.--(BUSINESS WIRE)--NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) announces expanded Avenova® consumer marketing programs designed to generate greater awareness of its antimicrobi...

8 months ago - Business Wire

EMERYVILLE, Calif.--(BUSINESS WIRE)-- #Avenova--NovaBay® Pharmaceuticals, Inc.

9 months ago - Business Wire

EMERYVILLE, Calif.--(BUSINESS WIRE)--NovaBay® Pharmaceuticals, Inc.

9 months ago - Business Wire

NovaBay Pharmaceuticals, Inc. (NYSE: NBY) shares are trading higher after the company announced the launch of its Avenova Facial Sanitizer on Walmart Inc.

9 months ago - Benzinga

EMERYVILLE, Calif.--(BUSINESS WIRE)--NovaBay expands Avenova's online distribution to include Walmart.com

9 months ago - Business Wire

NovaBay Pharmaceuticals, Inc. (NBY) CEO Justin Hall on Q2 2020 Results - Earnings Call Transcript

10 months ago - Seeking Alpha

EMERYVILLE, Calif.--(BUSINESS WIRE)--NovaBay reports second quarter 2020 financial results.

10 months ago - Business Wire

While penny stocks carry a high degree of risk, they could be a good place to look for value in today's market for investors that are willing to make short-term trades. These seven have potential cataly...

Other stocks mentioned: DGLY, FRSX, IBIO, XELA, XSPA
10 months ago - InvestorPlace

EMERYVILLE, Calif.--(BUSINESS WIRE)-- #Avenova--NovaBay Pharmaceuticals to Hold Second Quarter 2020 Conference Call on August 6

10 months ago - Business Wire

NovaBay Pharmaceuticals, Inc. (NBY) CEO Justin Hall on Q1 2020 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

NovaBay Pharmaceuticals, Inc. (NBY) CEO Justin Hall on Q4 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

NovaBay Pharmaceuticals, Inc. (NBY) CEO Justin Hall on Q3 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

NovaBay Pharmaceuticals' (NBY) CEO Justin Hall on Q2 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

NovaBay Pharmaceuticals (NYSE: NBY) shares are trading higher after the company said its plan of compliance was accepted by the New York Stock Exchange.

1 year ago - Benzinga

The 875-percent rally that propelled NovaBay Pharmaceuticals, Inc. (NYSE: NBY) shares from under 50 cents to over $3 Monday came on news of the micro-cap biotech making its Avenova eyecare product avail...

2 years ago - Benzinga

NovaBay Pharmaceuticals Inc.'s stock NBY, +484.91% has blasted off to a more-than 6-fold gain in extremely active Monday afternoon trading, after the specialty pharmaceutical company said its Avenova ey...

2 years ago - Market Watch

NovaBay Pharmaceuticals Inc. (NYSE: NBY) shares absolutely exploded on Monday after the company announced that its eye care treatment would be readily available on Amazon.

2 years ago - 24/7 Wall Street

Shares of nano-cap biopharmaceutical company NovaBay Pharmaceuticals, Inc. (NYSE: NBY) skyrocketed 220 percent Monday morning after the company inked an agreement to sell its eye care product on Amazon....

2 years ago - Benzinga

Shares of NovaBay Pharmaceuticals Inc. nearly doubled in active premarket trade Monday, after the biopharmaceutical company said its Avenova eye-care product is now available without a prescription on A...

2 years ago - Market Watch

NovaBay Pharmaceuticals, Inc (NBY) CEO Justin Hall on Q1 2019 Results - Earnings Call Transcript

2 years ago - Seeking Alpha

NovaBay Pharmaceuticals, Inc (NBY) CEO Justin Hall on Q4 2018 Results - Earnings Call Transcript

2 years ago - Seeking Alpha

About NBY

NovaBay Pharmaceuticals, Inc., a medical device company, develops products for the eye care markets in the United States and internationally. The company offers Avenova, a solution for cleansing and removing foreign materials, including microorganisms and debris from skin around the eye, including the eyelid; CelleRx Clinical Reset, a gentle and soothing facial spray; and NeutroPhase and PhaseOne for the wound care market. It also offers KN95 Masks. The company sells its products through distribution partners, as well as offers Avenova and Cell... [Read more...]

Industry
Biotechnology
IPO Date
Oct 26, 2007
CEO
Justin Hall
Employees
22
Stock Exchange
NYSEAMERICAN
Ticker Symbol
NBY
Full Company Profile

Financial Performance

In 2020, NBY's revenue was $9.93 million, an increase of 50.54% compared to the previous year's $6.60 million. Losses were -$11.04 million, 14.3% more than in 2019.

Financial Statements

Analyst Forecasts

According to 2 analysts, the average rating for NBY stock is "Strong Buy." The 12-month stock price forecast is 2.58, which is an increase of 252.84% from the latest price.

Price Target
$2.58
(252.84% upside)
Analyst Consensus: Strong Buy